Valuation: Fulgent Genetics, Inc.

Market Cap 57Cr 51Cr 47Cr 43Cr 80Cr 5.41TCr 81Cr 565.9Cr 224.75Cr 2.84TCr 213.8Cr 209.22Cr 8.99TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 57Cr 51Cr 47Cr 43Cr 80Cr 5.41TCr 81Cr 565.9Cr 224.75Cr 2.84TCr 213.8Cr 209.22Cr 8.99TCr EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.49x
Free-Float
48.86%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week+4.40%
Current month-4.56%
1 month-6.02%
3 months+7.06%
6 months+37.35%
Current year-20.00%
1 week 19.3
Extreme 19.3
21.35
1 month 19.3
Extreme 19.3
22.78
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
31.04
5 years 13.46
Extreme 13.46
109.55
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Founder

-2,127 0.0069%
02/09/26 Sell

Chief Technology Officer

-1,673 0.0055%
01/09/26 Tax

Chief Financial Officer

-2,087 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+1.11%+4.40%-10.31%-11.10% 57Cr
-0.33%-2.91%+10.38%+33.41% 12TCr
+3.04%+0.29%-1.23%+106.30% 9.74TCr
+4.32%+3.87%+126.51%+1,043.53% 5.92TCr
-0.35%+3.23%-5.94%+90.00% 2.9TCr
+10.35%+12.78%+40.61%+84.27% 2.69TCr
+1.63%+3.44%+38.62%+90.97% 2.67TCr
+3.13%+0.01%+31.54%+405.47% 2.11TCr
+0.95%+2.20%-16.82%-0.93% 2.06TCr
-0.13%-1.01%-6.23%+31.16% 1.69TCr
Average +2.38%+0.04%+20.71%+187.31% 4.15TCr
Weighted average by Cap. +2.19%-1.33%+25.88%+222.67%

Financials

2026 *2027 *
Net sales 33Cr 30Cr 27Cr 25Cr 47Cr 3.15TCr 47Cr 329.57Cr 130.89Cr 1.65TCr 124.51Cr 121.85Cr 5.24TCr 38Cr 34Cr 32Cr 29Cr 54Cr 3.64TCr 54Cr 380.24Cr 151.01Cr 1.91TCr 143.65Cr 140.58Cr 6.04TCr
Net income -11Cr -10Cr -9.28Cr -8.42Cr -16Cr -1.06TCr -16Cr -111.28Cr -44Cr -557.62Cr -42Cr -41Cr -1.77TCr -7.9Cr -7.09Cr -6.55Cr -5.94Cr -11Cr -750.38Cr -11Cr -78Cr -31Cr -393.32Cr -30Cr -29Cr -1.25TCr
Net Debt - -
Projected Income Statement - Annual - Fulgent Genetics, Inc.
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
28/26/28 $21.04 +1.64% 1,61,532
27/26/27 $20.70 +2.37% 3,55,832
26/26/26 $20.22 +0.60% 1,91,243
23/26/23 $20.10 +0.55% 2,40,059
22/26/22 $19.99 -0.70% 2,78,880
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Fulgent Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.70USD
Average target price
19.00USD
Spread / Average Target
-8.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fulgent Genetics, Inc.
  1. Stock Market
  2. Stocks
  3. FLGT Stock